Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jan 12;229(1):39-42.
doi: 10.1093/infdis/jiad237.

Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine: A Follow-up Study in Pakistan in 2020

Ali Faisal Saleem  1 , Sadia Parkar  1 , Syeda Mahjabeen Zehra  1 , Zaubina Kazi  1 , Asma Pethani  1 , Yiting Zhang  2 , Bernardo A Mainou  2 , Rocio Lopez Cavestany  3 , Grace Macklin  3 , Visalakshi Jeyaseelan  3 , Ondrej Mach  3
Affiliations
Clinical Trial

Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine: A Follow-up Study in Pakistan in 2020

Ali Faisal Saleem et al. J Infect Dis. .

Abstract

This was a follow-up study conducted in 2020 assessing changes in levels of type 2 poliovirus-neutralizing antibodies 2 years postimmunization in children who received inactivated poliovirus vaccine (IPV) in Karachi, Pakistan. Unexpectedly, the findings revealed an increase in seroprevalence of type 2 antibodies from 73.1% to 81.6% 1 year and 2 years after IPV, respectively. The increase in type 2 immunity could result from the intensive transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Karachi during the second year of IPV administration. This study suggests that the cVDPV2 outbreak detected in Pakistan infected large proportions of children in Karachi. Clinical Trials Registration . NCT03286803.

Keywords: Pakistan; duration of immunity; inactivated poliovirus vaccine; poliovirus; seroprevalence.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Publication types

Substances

Associated data